Correction: The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer (Cell Death & Disease, (2013), 4, 5, (e627), 10.1038/cddis.2013.158);The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

Cell Death and Disease

Volumn 4, Issue 5, 2013, Pages

  Hage, C ^a,b   Rausch, V ^a,b   Giese, N ^b   Giese, T ^b   Schonsiegel F ^a,b   Labsch, S ^a,b   Nwaeburu, C ^a,b   Mattern, J ^a,b   Gladkich, J ^a,b   Herr, I ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer stem cells; Pancreatic cancer; XL184

Indexed keywords

CABOZANTINIB; CASPASE 3; CD133 ANTIGEN; GEMCITABINE; SCATTER FACTOR RECEPTOR; SURVIVIN; TRANSCRIPTION FACTOR SOX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER MORPHOLOGY; CANCER RESISTANCE; CANCER STEM CELL; CELL ASSAY; CELL CULTURE; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPHEROID CELL; WESTERN BLOTTING;

EID: 84879372540     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/s41419-023-06385-9     Document Type: Erratum

References (33)

1. Gukovskaya AS, Pandol SJ. Cell death pathways in pancreatitis and pancreatic cancer. Pancreatology 2004; 4: 567-586.
2. Oberstein PE, Saif MW. First-line treatment for advanced pancreatic cancer. Highlights from the '2011 ASCO Gastrointestinal Cancers Symposium'. San Francisco, CA, USA. January 20-22, 2011. JOP 2011; 12: 96-100.
3. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
4. Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer 2013; 108: 1-8.
5. Rasheed ZA, Kowalski J, Smith BD, Matsui W. Concise review: emerging concepts in clinical targeting of cancer stem cells. Stem Cells 2011; 29: 883-887.
6. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
8. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
9. Simeone DM. Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin Cancer Res 2008; 14: 5646-5648.
10. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
11. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323.
12. Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011; 141: 2218-2227.e5.
13. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12: 89-103.
14. Li Y, Li A, Glas M, Lal B, Ying M, Sang Y et al. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci USA 2011; 108: 9951-9956.
15. You WK, Sennino B, Williamson CW, Falcon B, Hashizume H, Yao LC et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 2011; 71: 4758-4768.
16. Ryan DP. An open-label, phase II study of cabozantinib (XL184) in advanced pancreatic neuroendocrine and carcinoid tumors. Clinical Trials 2011; ClinicalTrials.gov Identifier: NCT01466036 Study ID Number: 11-274.
17. U.S. Food and Drug Administration: Cabozantinib 2013.
18. Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, Groth A et al. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 2009; 58: 949-963.
19. Abbott A. Cancer: the root of the problem. Nature 2006; 442: 742-743.
20. Flores ER, Lozano G. The p53 family grows old. Genes Dev 2012; 26: 1997-2000.
21. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
22. Krizhanovsky V, Lowe SW. Stem cells: the promises and perils of p53. Nature 2009; 460: 1085-1086.
23. Song Y, Washington MK, Crawford HC. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res 2010; 70: 2115-2125.
24. Suzuki A, Nakauchi H, Taniguchi H. Prospective isolation of multipotent pancreatic progenitors using flow-cytometric cell sorting. Diabetes 2004; 53: 2143-2152.
25. Oshima Y, Suzuki A, Kawashimo K, Ishikawa M, Ohkohchi N, Taniguchi H. Isolation of mouse pancreatic ductal progenitor cells expressing CD133 and c-Met by flow cytometric cell sorting. Gastroenterology 2007; 132: 720-732.
26. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-925.
27. Cometriq (cabozantinib capsules) prescribing information. Exelixis 2012.
28. Niwa H, Ogawa K, Shimosato D, Adachi K. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature 2009; 460: 118-122.
29. Valeriote F, van Putten L. Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res 1975; 35: 2619-2630.
30. Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J et al. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 2010; 70: 5004-5013.
31. Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I et al. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011; 9: 433-446.
32. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-279.
33. Rausch V, Liu L, Apel A, Rettig T, Gladkich J, Labsch S et al. Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment. J Pathol 2012; 227: 325-335. Development